

CTLA4 Circular RNA for Cancer Vaccine Research

Catalog Number:CVAC-ORNA-0437

DESCRIPTION	
Product Name	CTLA4 Circular RNA for Cancer Vaccine Research
Gene Name	CTLA4
Source	In vitro transcribed mRNA was further circularized to make this product as a circular RNA.
Alternative names	Sargramostim Plasmid DNA Melanoma Vaccine Adjuvant
SPECIFICATIONS	
Cap	
5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF	CTLA4
3'-UTR	3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail	
Modifications	N1-methyl-pseudouridine
Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol	Cholesterol
Lonizable Lipid	1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid	Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)
Storage	-80 °C
Buffer	PBS, pH7.5
Cryoprotectant	Trehalose
BACKGROUND	
Gene Accession	
Gene Alias	Sargramostim Plasmid DNA Melanoma Vaccine Adjuvant
Background	Description: A vaccine adjuvant consisting of a plasmid DNA encoding sargramostim (a granulocyte macrophage-colony stimulating factor). Upon administration, expressed sargramostim may stimulate a cytotoxic T cell response enhancing the host immune response to a concomitantly administered melanoma vaccine. (NCIT_C2430).